Here is some Vivus news:
biz.yahoo.com
Thursday October 26, 10:04 am Eastern Time
Press Release
VIVUS Opens Patient Enrollment for Its Female Sexual Dysfunction Clinical Study
MOUNTAIN VIEW, Calif.--(BW HealthWire)--October 26, 2000--VIVUS, Inc.
(Nasdaq NM: VVUS - news) today announced that they have begun patient enrollment
in the clinical program for the Company's female sexual dysfunction (FSD) product,
ALISTA(TM).
It is estimated that over 40% of women report some form of FSD, including both organic
and psychogenic causes. Researchers have classified the range of symptoms seen in FSD
into four subcategories: desire, arousal, orgasmic and sexual pain disorders. The VIVUS
clinical program is designed to evaluate ALISTA in women with a primary complaint of
sexual arousal disorder, or FSAD.
``This is an exciting time for VIVUS as we expand our clinical development program to
include products to help women improve their quality of life,'' said Leland F. Wilson,
President and CEO. ``Results from this initial clinical study of ALISTA will aid in the
design of larger studies that are required for the global regulatory approval process.''
ALISTA is a proprietary formulation of alprostadil applied locally to the female genitalia.
Alprostadil is a synthetic version of a naturally occurring vasodilating agent found in the
body. It is the same active ingredient found in VIVUS' product, MUSE®, used to treat
male erectile dysfunction. ALISTA is believed to increase blood flow to the female
genitalia, thereby promoting engorgement and other natural processes that occur during
sexual stimulation.
With both issued and pending patents, the Company believes it has the dominant patent
position for the local delivery of prostaglandins, such as alprostadil, in the treatment of
women with FSD. Local administration has the potential to deliver high concentrations of
active agent to the site of action while reducing exposure to the rest of the body, thereby
limiting potential side effects.
VIVUS, Inc. is a specialty pharmaceutical company engaged in the development of
innovative therapies for quality-of-life disorders in men and women, with a focus on
sexual dysfunction. The Company developed and markets in the U.S. the product
MUSE® (alprostadil) and the medical device ACTIS®, two innovations in the treatment
of erectile dysfunction (ED). VIVUS has partnered with Abbott Laboratories (NYSE:
ABT - news) for the international marketing and distribution of its male ED products. The
Company also has ongoing R&D programs in premature ejaculation and
future-generation ED products.
Note to editors and investors: Additional written materials, recent releases and Company
information are available through a variety of sources, including the VIVUS home page
(www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
This news release contains forward-looking statements that involve risks and uncertainties
regarding VIVUS Inc.'s operations and future results. Please see the Company's filings
with the Securities and Exchange Commission including, without limitation, the Company's
Form 10-Ks and Form 10-Qs, which identify specific factors that may cause actual
results or events to differ materially from those described in the forward-looking
statements. |
